Vertex Pharmaceuticals Files 8-K Disclosure
Ticker: VRTX · Form: 8-K · Filed: Dec 20, 2024 · CIK: 875320
Sentiment: neutral
Topics: regulatory-filing, sec
Related Tickers: VRTX
TL;DR
VRTX filed a routine 8-K, no major news.
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on December 20, 2024, to report information under Regulation FD. The filing does not contain specific details about new events, agreements, or financial figures, but rather serves as a standard disclosure.
Why It Matters
This filing indicates Vertex Pharmaceuticals is adhering to its regulatory disclosure obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not contain information that would immediately impact the company's risk profile.
Key Players & Entities
- VERTEX PHARMACEUTICALS INC / MA (company) — Registrant
- 0000875320-24-000231 (filing_id) — Accession Number
- December 20, 2024 (date) — Filing Date
- 50 Northern Avenue, Boston, MA 02210 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing by Vertex Pharmaceuticals?
The purpose of this 8-K filing is to report information under Regulation FD as of December 20, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is December 20, 2024.
What is Vertex Pharmaceuticals' principal executive office address?
Vertex Pharmaceuticals' principal executive office is located at 50 Northern Avenue, Boston, Massachusetts 02210.
What is the company's telephone number?
The company's telephone number is (617) 341-6100.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-12-20 15:51:45
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
- $370,269 — st for ALYFTREK in the United States of $370,269 on an annual basis ($28,404 per 28-day
- $28,404 — States of $370,269 on an annual basis ($28,404 per 28-day pack). SEC Information.
Filing Documents
- vrtx-20241220.htm (8-K) — 22KB
- 0000875320-24-000231.txt ( ) — 142KB
- vrtx-20241220.xsd (EX-101.SCH) — 2KB
- vrtx-20241220_lab.xml (EX-101.LAB) — 21KB
- vrtx-20241220_pre.xml (EX-101.PRE) — 12KB
- vrtx-20241220_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK. We have established a wholesale acquisition cost for ALYFTREK in the United States of $370,269 on an annual basis ($28,404 per 28-day pack). SEC Information. The information set forth in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: December 20, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer